NTRK1 and Cirrhosis: Regarding systemic chemotherapy, sorafenib, a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), is used as the first-line setting for patients with advanced HCC because almost all HCC patients have cirrhosis, chemotherapies, or major resections are not well tolerated.